Physician profile
Mala Gupta
NPI 1407973001
$1,247.30
in general payments reported to CMS, 2019-2025
21 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.58 · 2020: $22.74 · 2021: $14.59 · 2022: $214 · 2023: $370 · 2024: $296 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899 · Education: $24.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.29 |
| Education | $24.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $219.17 | 2021-2025 | |
| Corium, LLC | $160.73 | 2023-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $118.53 | 2022-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $97.70 | 2019-2025 | Rexulti |
| Tris Pharma INC | $81.83 | 2022-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $81.35 | 2023-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $68.10 | 2019-2022 | |
| Bausch Health US, LLC | $66.10 | 2022-2025 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $58.58 | 2022-2024 | Trintellix |
| Axsome Therapeutics, INC. | $50.64 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.58 | 2022-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $36.38 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $27.92 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.59 | 2023 | Rexulti |
| Alkermes, INC. | $19.58 | 2023 | Aristada, Lybalvi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $14.93 | 2023 | Wakix |
| Neurocrine Biosciences, INC. | $14.90 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.88 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.74 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.08 | 2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $13.99 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mala Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.